Two new studies highlight how ADHD medications not only reduce the risk of self-harm, accidents, and criminal behavior but also promote healthy brain development in children when treatment starts early.
The studies show that both stimulant and nonstimulant medications offer wide-ranging protective effects for individuals with ADHD. Researchers say these benefits apply across a person’s lifespan — and are especially powerful when treatment begins in childhood.
Medication Linked to Fewer Harmful Outcomes
A large-scale population study using Swedish National Registers tracked nearly 250,000 individuals aged 4 to 64 who took ADHD medications between 2006 and 2020. The results showed significant reductions in the risk of:
- Self-harm by 15% to 29%
- Unintentional injury by 7% to 13%
- Traffic crashes by 13% to 29%
- Criminal activity by 16% to 27%
Researchers looked at data across three periods: 2006–2010, 2011–2015, and 2016–2020. They observed that medication use did not become less effective over time, even as prescriptions became more common.
However, as more individuals with milder ADHD symptoms began receiving prescriptions, the average effect of medication slightly decreased. This, experts say, does not mean the medication works less — but that new patients may not face the same level of risk to begin with.
“In recent years, people diagnosed with ADHD often have fewer or milder symptoms compared to those diagnosed 15 years ago,” researchers noted.
ADHD Diagnoses and Prescriptions on the Rise
From 2006 to 2020, ADHD medication prescriptions rose significantly:
- From 0.4% to 1.6% overall
- From 0.8% to 2.4% in children
- From 0.2% to 1.1% in adults
Prescriptions for women and girls aged 15 to 44 increased from 0.9% in 2003 to 4% in 2015. During the early period studied, women showed the strongest protective effects from medication. This is likely because only those with the most severe symptoms were diagnosed and treated in the past — especially given how underdiagnosed girls with ADHD have historically been.
The study emphasizes that the rise in prescriptions is not due to an actual increase in ADHD cases. Instead, it reflects better research, greater awareness, and improved diagnostic tools.
A separate review published in the Journal of Attention Disorders confirmed that ADHD rates have not increased between 2020 and 2024.
“Even as prescriptions rise, the benefits of ADHD medication remain clear,” the researchers concluded.
Early Treatment Helps Brain Development
In the second study, researchers looked at how methylphenidate (a common ADHD medication sold as Ritalin and Focalin) affects brain growth.
Using MRI brain scans over five years, they studied 180 children — some with ADHD, others without — and split them into three groups:
- Early exposure group: Took methylphenidate before age 12
- Late exposure group: Started treatment after age 12
- Control group: No ADHD or medication
The early exposure group showed significant growth in the brain’s frontal lobe, the area responsible for decision-making, impulse control, and attention. This group also had fewer oppositional behaviors like defiance or arguing, according to parent reports.
However, the late-exposure group showed no notable brain growth or behavioral changes.
“These results suggest that starting medication before age 12 may lead to more positive changes in brain development,” the authors wrote. “It highlights how important early treatment can be for children with ADHD.”
Political Pushback Sparks Fears Among Families
Despite this growing body of evidence, ADHD medications remain under political scrutiny.
In May, the MAHA Commission — led by Health and Human Services Secretary Robert F. Kennedy, Jr. — released a report claiming that ADHD is being overdiagnosed in American children. The report also questioned whether stimulants offer long-term benefits. ADHD experts widely criticized the report, pointing to decades of solid research supporting the effectiveness of these treatments.
Dr. Russell Barkley, a top ADHD expert, responded in a video:
“Just because more people are getting treatment doesn’t mean it’s a bad thing. It could mean we’re finally helping people who’ve been overlooked for years.”
In August, the MAHA Commission is expected to release policy recommendations that could affect access to medications for ADHD, autism, obesity, and other conditions.
Families Voice Alarm at Potential Access Cuts
Concerns are growing among people who rely on ADHD medication. Many fear new restrictions could limit their ability to manage symptoms and live functional lives.
A Michigan reader from ADDitude magazine shared her experience:
“I hold a high-paying job, but during the stimulant shortages, I cried at night thinking I’d lose it. I need this medication to function. We should expand access — not limit it.”
Another reader from Texas expressed worry for her family:
“My daughter and I both have ADHD. After years of trial and error, we finally found a medication that works. If it’s taken away, I’ll consider leaving the country for our health.”
Long-Term Data Supports Medication Benefits
The new findings join a long list of studies — spanning over four decades — showing that ADHD medications can protect against serious outcomes like accidents and mental health crises. They can also help normalize brain development, especially when started early.
As the national debate over ADHD diagnosis and treatment continues, experts stress the importance of listening to the science and supporting families who depend on these medications to live healthy lives.
Related topics:
